Women’s Bone Health Guide: Osteoporosis & Fracture Prevention
Bone health is about preventing fractures and preserving function. A scan result is one part of that decision, alongside previous fractures, health history, medicines and falls.
A clear next step
- Name the change or care question.
- Check whether help is urgent.
- Bring your history and priorities.
- Agree the next action and review.
Part of the Women’s Health research series.
On this page: choose your question
- The short answer
- Bring the history that a scan cannot supply
- Understand what DXA contributes
- Use screening guidance with its boundaries
- Connect bone health with everyday safety
- Compare treatment with a continuation plan
- Track function as well as a result
- Your fracture-prevention discussion
- Frequently asked questions
- Sources and editorial method
The short answer
The USPSTF’s 2025 recommendation supports osteoporosis screening for women 65 or older and younger postmenopausal women assessed as being at increased risk. Known osteoporosis, fragility fractures and secondary causes need a different clinical pathway from routine screening. [1]
Educational information for adults, primarily in a US care context. Use a qualified clinician for diagnosis and treatment. Do not change prescribed medicines from this guide. Guidance may differ by location, history and organs present.
Bring the history that a scan cannot supply
Record previous fractures and how they happened, height changes, falls, family history, menstrual or menopause history and medicines that could affect bone. NIAMS also emphasizes diet, activity and relevant medical conditions. Ask whether a suspected fracture needs immediate assessment rather than waiting for a screening appointment. [2]
Bring original scan reports if available. A note of the testing date and site is more useful than remembering that a result was “a little low.” Ask whether another service already has the information before repeating a test.
Understand what DXA contributes
NIAMS describes DXA measurement, usually at the hip and spine, as a standard way to assess bone mineral density. Its role differs from a quick peripheral or heel assessment. A clinician interprets the measurement with the broader history rather than treating every device as interchangeable. [2]
Ask: “Is this a diagnosis, a risk assessment or monitoring? What will change because of the result?” If numbers differ between reports, ask about the comparison before assuming a large biological change.
Use screening guidance with its boundaries
For postmenopausal women younger than 65, USPSTF describes assessing risk factors and then using a clinical risk tool when appropriate to help decide about screening. Its routine-screening recommendation does not cover people with known fragility fracture or osteoporosis from certain medical conditions or medicines. [1]
| Situation | Useful question |
|---|---|
| Routine screening | Does my age and assessed risk fit the screening recommendation? |
| Previous low-trauma fracture | Do I need a treatment assessment rather than another screening decision? |
| Long-term medicine exposure | Does this create a separate bone-health pathway? |
| Repeat scan proposed | Why repeat now, and what result would change management? |
Connect bone health with everyday safety
Discuss suitable activity, strength and balance, food adequacy, smoking and fall risks. Nutrition supports care, but a supplement should not be assumed to replace treatment for established osteoporosis. NIAMS describes care that can combine nutrition, activity, fall prevention and medicines. [2]
Choose a practical home check: safe access to frequently used items, adequate light on the route to the bathroom, and a discussion of dizziness or mobility difficulty. Ask for individualized advice if pain, previous fracture or a medical condition limits movement.
Compare treatment with a continuation plan
Ask why a particular medicine is offered, which fractures it aims to prevent, how it is taken, relevant adverse effects and when benefit is reviewed. Include dental, kidney and other relevant health history in the appointment rather than selecting treatment from a product comparison alone.
Before starting or stopping, ask whether interruption requires a specific plan. Record who coordinates repeat assessment and prescriptions. This guide does not provide a medicine schedule or authorize changes to an existing treatment.
Track function as well as a result
A worthwhile plan should address confidence moving around, falls, pain, daily tasks and adherence, alongside clinical measurements. Keep a record of new fractures and symptoms, and tell the responsible clinician about problems following treatment.
The menopause guide covers hormone-related care decisions. The nutrition guide separates dietary adequacy from broad fracture-prevention marketing claims.
Your fracture-prevention discussion
Copy these prompts into a private note and bring them to your appointment. This original planning aid is not a validated score or diagnostic test.
- Fractures and circumstances: write your note and one question.
- Falls, height or mobility changes: write your note and one question.
- Previous DXA date/report: write your note and one question.
- Relevant medicines and conditions: write your note and one question.
- Food/activity/access questions: write your note and one question.
- Treatment and next review plan: write your note and one question.
Never delay urgent care to finish a diary or worksheet. Keep only the details you are comfortable recording.
Frequently asked questions
Does every woman need a DXA at 40?
No. The cited screening recommendation uses age, menopause status and assessed risk, with separate pathways for known disease or secondary causes.
Is a heel test the same as central DXA?
No. Ask which test was done and whether further assessment is needed.
Are calcium products a complete osteoporosis treatment?
No. Nutrient adequacy is only one part of a fracture-prevention plan.
Sources and editorial method
Prepared for FitnessLifeMag by Biraj Kh., Founder & Editor. This is an AI-assisted editorial synthesis of selected public guidance, with targeted source checks on November 16, 2026. It has no independent clinician review and is not a systematic review or personalized medical advice.
We distinguish screening from symptom assessment, laboratory markers from health outcomes, and ingredient research from finished-product evidence. The source notes describe material access limits and recommendation dates. We did not inspect every underlying study or independently test products.
- USPSTF: Osteoporosis Screening, 2025 final. Screening population, younger postmenopausal risk assessment and exclusions inspected.
- NIAMS: Osteoporosis—Diagnosis, Treatment and Steps to Take. Public DXA, fracture prevention and treatment overview; screening ages checked against USPSTF.